Core Viewpoint - Hendi Pharmaceutical (301211.SZ) reported a decline in revenue and net profit for the first half of 2025, indicating challenges in financial performance while continuing to advance its investment projects [1] Financial Performance - The company's operating revenue for the first half of 2025 was 235 million yuan, a year-on-year decrease of 2.93% [1] - Net profit attributable to shareholders was 18.5471 million yuan, down 72.92% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 4.4162 million yuan, a significant decrease of 93.21% year-on-year [1] - Basic earnings per share were 0.06 yuan [1] Corporate Actions - The company plans to increase its share capital by 4.5 shares for every 10 shares held by all shareholders [1] - During the reporting period, the company actively promoted the implementation of fundraising projects [1] Project Developments - The ibuprofen raw material drug safety and environmental upgrade project has passed the joint acceptance inspection by the construction department and has begun trial production [1] - The high-end pharmaceutical formulation internationalization project obtained the construction permit on June 5, 2025, and has entered the construction phase [1]
亨迪药业(301211.SZ)发布上半年业绩，归母净利润1854.71万元，下降72.92%